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Aim. Hyul-bu-chuke-tang (HCEt) is a well-known traditional herbal medicine that is used for the treatment of ischemic
cerebrovascular disorders. We investigated the acute eﬀects of HCEt on erythrocyte deformability and cerebrovascular CO2
reactivity (CVR) in healthy male subjects. Materials and Methods. We examined erythrocyte deformability in an HCEt group
(n = 14) and a control group (n = 10). CVR was measured using hyperventilation-induced CO2 reactivity of the middle cerebral
arteryandtranscranialDoppler(TCD)intheHCEtgroup(n = 11).Ahistoricalcontrolgroup(n = 10)ofCVRmeasurementswas
also created from our previous study. All measurements were performed prior to and 1, 2, and 3 hours after HCEt administration.
Results. HCEt signiﬁcantly improved erythrocyte deformability 1 hour after administration compared to the control group
(2.9 ± 1.1% versus −0.6 ± 1.0%, P = 0.034). HCEt signiﬁcantly improved the CVR 2 hours after administration compared to
the historical control group (9.1 ± 4.0% versus −8.1 ± 4.1%, P = 0.007). The mean blood pressure and pulse rate did not vary
from baseline values in either group. Conclusions. We demonstrated that HCEt improved erythrocyte deformability and CVR. Our
ﬁndings suggest that an improvement in erythrocyte deformability contributes to HCEt’s eﬀect on cerebral microcirculation.
1.Introduction
Traditional herbal medicine is widely used in Asia to
optimize the treatment of cerebrovascular disease with con-
ventionaltherapy[1].Hyul-bu-chuke-tang(HCEt,knownas
Xue-fu-zhu-yu-tang in Chinese) is one of the best-known
traditional herbal medicines for the treatment of cerebral
infarction in Korea. The therapeutic eﬀect of HCEt on
ischemic vascular diseases has been veriﬁed recently [2, 3].
However, HCEt is a complex of 11 medical plants, and its
therapeutic mechanism is likely complicated.
Traditional Chinese Medicine suggests that HCEt im-
pacts blood stasis syndrome, which is a pathological state of
blood stagnancy in a certain area of the body [4]. Impair-
ments in hemorheology and microcirculation play impor-
tant roles in the pathophysiology of blood stasis syndrome,
which is consistent with TCM theory [5, 6]. HCEt reduces
platelet aggregation and enhances erythrocyte deformability
and blood ﬁltration rates in vivo [7]. Erythrocyte deforma-
bility is an important factor for microvasculature perfusion
[8]; diminished erythrocyte deformability increases micro-
circulatory resistance [9]. Hemorheological factors modify
blood ﬂuidity and blood ﬂow behavior [5]. However, the
eﬀects of HCEt on erythrocyte deformability and cerebral
microcirculatory blood ﬂow in humans have not been
researched extensively.
The present study investigated the acute eﬀects of HCEt
on erythrocyte deformability in normal subjects. We also
measured cerebrovascular CO2 reactivity using transcranial
Doppler ultrasonography (TCD) to preliminarily investigate
the eﬀect of HCEt on cerebral microcirculation.
2.MaterialsandMethods
Two consecutive investigations were included in our study.
Theﬁrstseriesmeasurederythrocytedeformabilityfollowing2 Evidence-Based Complementary and Alternative Medicine
Table 1: Constituents of hyul-bu-chuke-tang.
Components Part used Percentage
Angelica acutiloba Kitagawa (Umbelliferae) Root 13.3
Prunus persica (L.) Batsch (Rosaceae) Seed 17.7
Rehmannia glutinosa Liboschitz (Scrophulariaceae) Root 13.3
Carthamus tinctorius L. (Compositae) Flower 13.3
Achyranthes japonica (Miq.) Nakai (Amaranthaceae) Root 4.4
Citrus aurantium L. (Rutaceae) Fruit 8.8
Paeonia lactiﬂora Pall. (Ranunculaceae) Root 8.8
Platycodon grandiﬂorum (Jacq.) A. DC. (Campanulaceae) Root 8.8
Cnidium oﬃcinale Makino (Umbelliferae) Root 6.6
Bupleurum falcatum Linne (Umbelliferae) Root 2.2
Glycyrrhiza glabra L. (Leguminosae) Root 2.2
HCEt administration using a microﬂuidic ektacytometer in
24 healthy subjects. The second series evaluated the CVR
following HCEt administration using TCD in 11 healthy
subjects.
2.1. Subjects. Thirty-ﬁve healthy male volunteers (mean age:
27.1 ± 0.5 (S.D) years)) participated in the study. The
Institutional Review Board at the Kyung Hee Medical Centre
approved this study, and all participants signed written
consentforms.Noneofsubjectshadahistoryofneurological
disorders, such as stroke, head injury, psychiatric disorders
(e.g., mental retardation, schizophrenia, and depression),
hypertension, diabetes mellitus, drug abuse, alcohol depen-
dence/abuse, or a disease or previous surgery that could
inﬂuence drug absorption. The subjects abstained from
smoking and drinking alcohol, coﬀe e ,o rt e af o r1 2h o u r s
prior to examination.
2.2. Preparation of Hyul-Bu-Chuke-Tang (HCEt). The De-
partment of Preliminary Pharmaceutical Preparation of the
Kyung Hee University Korean Medical Centre (KHUKMC)
synthesized the HCEt. HCEt was prepared as dry extract
granules, 6g per pouch, which contained the 11 species
of medicinal herbs in Table 1. Kim in the Department of
Pharmaceutics at KHUKMC identiﬁed the plant materials,
and voucher specimens (number 10-10-03) were deposited
in the Herbarium of the Department of Pharmaceutics at
KHUKMC. Crude herbs (Persicae Semen 424 g, Angelical
Gigantis Radix 320g, Gehmannial Rhizoma 320g, Carthami
Flos 320g, Achyranthis Bidentatae Radix 320g, Aurantii
Fructus 216g, Paeoniae Radix Rubra 216g, Platycodi Radix
216g, Cnidii Rhizoma 160g, Bupleuri Radix 160g, and
Glycyrrhizae Radix 160g; total herbs 2832g) were cut into
small pieces, and the herb mixture was extracted in a
reﬂux condenser for 3h with 20.000mL of hot water. The
solution was ﬁltered through ﬁlter paper (Whatman no. 1)
and concentrated using a spray drying process (drug-extract
ratio: 3.75:1). The dry extracts were granulated using 3
diﬀerent binders, lactose (200g), polyvinylpyrrolidone (PVP,
160g), dextrin (300g) and ethanol (1400mL). The ethanol
was evaporated after the binding procedure.
2.3.MeasurementofErythrocyteDeformability. Weexamined
erythrocyte deformability in the HCEt group (14 healthy
males, mean age: 28.9 ± 3.4 (S.D) years) and the control
group (10 healthy males, mean age: 27.3 ± 1.3y e a r s ) .T h e
HCEt extract was administered orally at 8 am. The measure-
ments were performed prior to and 1, 2, and 3 hours after
HCEt administration. Four blood samples were obtained
from each subject. The control group did not receive treat-
ment.
A Rheoscan-D microﬂuidic ektacytometer (Rheo Medit-
ech, Seoul, Korea) measured erythrocyte deformability. One
drop of blood was obtained from each volunteer’s ﬁngertip
using a ﬁnger prick (Seahan Medical, Seoul, Korea). The
erythrocyte suspension was prepared by mixing 6.0µL whole
blood and 0.5mL of a highly viscous PVP solution (31mPa)
in phosphate-buﬀered saline (0.14mM). A 0.5-mL aliquot of
the erythrocyte suspension was placed in the test chamber
of a disposable kit, which included a microchannel (Rheo
Meditech, Seoul, Korea). Diﬀerential pressure drove the
erythrocyte suspension through the microchannel (0.2×4×
40mm) of the disposable kit, and the waste was collected in
a waste chamber. A laser beam (635nm wavelength) from a
1.5-mW laser diode passed through the diluted erythrocyte
suspension during the ﬂow. The diﬀraction pattern of the
moving erythrocytes at plural shear stresses was projected
onto a screen, and the images were captured by a CCD-
video camera every 0.5sec. The images were analyzed using
an ellipse-ﬁtting computer program. The average shear stress
ranged from 0 to 30Pa. The elongation index (EI) of
erythrocyte deformability was deﬁned as follows [10]: EI =
(L − W)/(L + W), where L and W are the major and
minoraxesoftheerythrocyteellipse,respectively.Themicro-
channel was discarded after each measurement.
2.4. Measurement of Cerebrovascular CO2 Reactivity (CVR)
UsingTranscranialDopplerUltrasonography. Weinvestigated
cerebrovascular reactivity using TCD. CVR was measured
using hyperventilation-induced carbon dioxide reactivity
of the middle cerebral artery in 11 healthy young male
volunteers (mean age: 24.8 ± 1.1 years) in the HCEt group.
All participants received 1 pouch of HCEt extract at 8 a.m.Evidence-Based Complementary and Alternative Medicine 3
TCD was performed prior to HCEt administration and 1, 2,
and 3h after HCEt administration.
CVR was assessed during 1-min hyperventilation-in-
duced hypocapnia, which is similar to a previous TCD study
that used a Multi-Dop X4 system (Compumedics DWL,
Singen, Germany) [11, 12]. Each subject was examined in
the supine position. The 2-MHz-pulsed Doppler probe
was placed on the temporal region (ultrasonic window). A
removable bilateral probe holder (LAM-Rack; Compumed-
ics DWL) was used to avoid probe shifting and permit con-
tinuous measurement. All measurements commenced after
the subjects had stabilized (approximately 5min). The mean
blood ﬂow velocity of the middle cerebral artery was calcu-
lated continuously as the time-averaged maximum velocity
over the cardiac cycle, which was computed from the
envelope of the maximum frequencies. CVR was determined
as the percent change in mean blood velocity per change of
PETCO2 as calculated by the following formula [13]:







where Vrest is the mean blood velocity in the normocapnic
condition for 5min prior to the initiation of hyperventila-
tion. Vhypocapnia is the mean blood velocity of the latter half
of the 1min-hyperventilation period, and ΔPETCO2 (partial
pressure of end-tidal carbon dioxide; a measure of the
amount of carbon dioxide in the exhaled air) is the change
in PETCO2 from baseline to maximal hyperventilation. CO2
reactivity was expressed as %/min.
We recorded blood pressure, heart rate, and PETCO2
simultaneously using a Cardiocap S/5 capnometer (Datex-
Ohmeda, Helsinki, Finland) to monitor the covariates that
may regulate cerebral artery blood ﬂow. Blood pressure and
pulse rate were measured under stable normocapnic condi-
tions prior to hyperventilation. These measurements were
performed 4 times at 2-min intervals to determine the mean
blood pressure. An oxymetry apparatus on the subject’s
ﬁnger simultaneously monitored the pulse rate. A Cardiocap
S/5 collector-connected nasal prong monitored PETCO2,a n d
each subject only breathed through the nose during the
study. The Cardiocap S/5 collector software program calcu-
lated the mean pulse rate and PETCO2 at certain timepoints
during the assessment.
A historical control group that included placebo control
data on TCD-measured CVR was also created from our
previous study [11]. We previously investigated CVR in 2006
in 10 healthy young male volunteers (age: 26.1 ± 1.8y e a r s )
who had received a placebo control drug using an identical
method and device as the current study.
2.5. Statistical Analysis. We utilized the Statistical Package
for Social Science version 12.0 for Windows (SPSS, Chicago,
IL). Data are summarized as the means ± standard deviation
or means ± standard mean error. Paired t-test-compared
variables prior to and after administration in each group.
Independent t-test-compared variables in the HCEt and con-
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Figure 1: Change of erythrocyte deformability in the HCEt group
(n = 14) and the control group (n = 10) at each time point. All
values are the percent change compared to baseline. The vertical
bars represent the means ± S.E.M. The P values were obtained from
independent t-test. HCEt: hyul-bu-chuke-tang; h: hour. #P < 0.05
compared to the control group.
3. Results
The index of erythrocyte deformability (EI) at 1, 2, and 3h
was signiﬁcantly greater than baseline in the HCEt group
(Figure 1) .T h eE Ii nt h ec o n t r o lg r o u pw a sn o ta l t e r e d .
HCEt administration signiﬁcantly improved erythrocyte
deformability after 1 hour compared to the control group
(2.9 ± 1.1% (S.E.M) in 14 subjects versus −0.6 ± 1.0% in 10
subjects: 95% conﬁdence interval for diﬀerence = 0.3–6.8%,
P = 0.034). No diﬀerence in age between the two groups was
observed.
HCEt increased CVR above baseline values at 1 and 2h
after administration. A comparison of the CVR data in the
HCEt group to the historical control group using Student’s
t-test revealed signiﬁcant improvement in the HCEt group
(9.1 ± 4.0% (S.E.M) in 11 subjects versus −8.1 ± 4.1% in
10 subjects: 95% conﬁdence interval for diﬀerence = 5.2–
29.4%, P = 0.007). No diﬀerence in age between the two
groups was observed.
The erythrocyte deformability (n = 14) and CVR (n =
11) data of individuals in the HCEt group are shown in
Figures 3(a) and 3(b).
The mean blood pressures and pulse rates did not vary
signiﬁcantly from baseline values during the 3-hour TCD
procedure in either group (Table 2).
4. Discussion
This study demonstrated that HCEt improved erythrocyte
deformability and increased CVR in young healthy subjects.
Our results suggest that HCEt exhibits acute eﬀects on
cerebral microcirculation and that HCEt diminished blood
ﬂow resistance in distal vessels by improving erythrocyte
deformability, which contributed to the increase in CVR.4 Evidence-Based Complementary and Alternative Medicine
Table 2: Mean blood pressures and pulse rates during the TCD examination.
Baseline After administration
1h 2h 3h
Mean BP (mmHg) HCEt (n = 11) 84.7 ±5.88 4 .9 ±4.18 4 .6 ±5.88 3 .6 ±4.4
Control (n = 10) 85.8 ±6.58 9 .5 ±6.08 5 .7 ±7.58 6 .9 ±7.7
Pulse Rate (bpm) HCEt (n = 11) 66.4 ±9.26 5 .2 ±7.26 5 .2 ±7.26 5 .5 ±7.7
Control (n = 10) 71.0 ±8.76 6 .7 ±9.66 4 .1 ±9.46 4 .1 ±9.7
The data are presented as the means ± standard deviation; no signiﬁcant diﬀerence between baseline and 1, 2, and 3h values was detected by paired t-test.
HCEt: hyul-bu-chuke-tang; BP: blood pressure; bpm: beats per minute; h: hour.
We demonstrated that HCEt reduced microcirculatory
resistance by improving erythrocyte deformability. Erythro-
cytes must deform to enter microvessels, such as capillaries,
which maintain a smaller diameter than erythrocytes [8].
An increase in erythrocytes deformability eases the passage
through a capillary, which increases the number of perfused
capillaries in the vascular bed, (i.e., capillary recruitment)
[14]. The improvement in blood ﬂow was due to an
increase in capillary recruitment [15]. Alterations in ery-
throcyte deformability primarily inﬂuence microcirculation
resistance in vessels with dimensions that are similar to
erythrocyte size (approximately 7-8µm) [16].
We also conﬁrmed a 9.1% increase in CVR for 2
hours after HCEt administration, which was signiﬁcant
compared to baseline (Figure 2). This result suggests that
HCEt increased regional resting cerebral blood ﬂow. CVR
is the change in cerebral blood ﬂow velocity in response
to changes in PCO2, and it is a reliable index of relative
changes in cerebral blood ﬂow [17–20]. Cerebrovascular
CO2 reactivity (CVR) reﬂects the consequent response
of arterioles in the cerebral vascular bed to the dilatory
CO2 stimulus [13]. Ackerman demonstrated that CVR
is proportional to the regional resting blood ﬂow/blood
pressure ratio and determined this ratio as conductance
(i.e., the reciprocal of cerebrovascular resistance) [17, 20].
We continuously monitored blood pressure and heart rate
during CVR examinations and conﬁrmed that these values
were constant (Table 2). Therefore, increases in CVR after
HCEt administration were proportional to the increase in
regionalrestingbloodﬂow[20,21].WepostulatedthatHCEt
increased regional resting blood ﬂow as a result of reduced
cerebral microcirculatory resistance.
This study established the eﬃcacy of HCEt on ery-
throcyte deformability in normal human subjects for the
ﬁrst time. We also demonstrated that improved erythrocyte
deformability contributed to the eﬀect of HCEt on cerebral
microcirculation. However, the relationship between the
HCEt-induced hemorheological eﬀect and microcirculatory
resistance reduction should be interpreted with caution.
Individual data changes were dynamic for 3 hours. The
time to maximum HCEt eﬀect was not consistent in either
parameter in each subject. We must consider that a vasodila-
tory eﬀect of HCEt directly contributed to the reduction
in blood ﬂow resistance. The vasodilatory eﬀect of HCEt
has been the focus of previous research. HCEt increases
NO production in TNF-r-treated vascular smooth muscle




























Figure 2: Change of cerebrovascular CO2 reactivity (CVR) in the
HCEt group (n = 11) at each time point. aFor comparison, CVR
data are also shown for historical control group of 10 healthy young
male subjects matched with for age and who received placebo. All
values are the percent change compared to baseline. The vertical
bars represent the means ± S.E.M. The P values were obtained from
independent t-test. HCEt: hyul-bu-chuke-tang; h: hour.
#P<0.05
compared to the historical control group.
cells from rat aorta, elevates serum NO levels and the NO
synthase system in swine after acute myocardial infarction,
and decreases serum levels of asymmetric dimethylarginine
(ADMA), a nitric oxide inhibitor, in atherosclerotic rabbits
[22–24]. However, we suggest that the vasodilatory eﬀect
and rheological behavior acted simultaneously due to NO
regulation by HCEt. Figures 3(a) and 3(b) illustrate that
the distribution patterns of variables between erythrocyte
deformability and CVR were remarkably similar among
individuals for 2 hours. Externally generated NO also
increaseserythrocytedeformabilityinhealthymalevolunteer
blood samples [25]. The antioxidant defense mechanism
determines the grade of RBC structural rigidity [26]b e c a u s e
the RBC membrane is rich in polyunsaturated fatty acids,
which creates susceptibility to oxidative damage [27]. The
petals of Carthamus tinctorius L. (Saﬄower) of HCEt
exhibits a protective eﬀect on oxygen-free radical-induced
oxidativedamagetoerythrocytemembranes,inhibitsplatelet










































































Figure 3: The erythrocyte deformability (a) and cerebrovascular CO2 reactivity (b) over time in each individual who received HCEt. All
values are the percent change compared to baseline. h: hour; CVR: cerebrovascular CO2 reactivity.
circulation [28, 29]. Achyranthes japonica Radix impacts
antioxidant and ﬁbrinolytic eﬀects, and it is used for blood
stasis in the peripheral circulatory system [30, 31]. The dried
rhizomes of Cnidium oﬃcinale are widely used for blood
circulation due to its free radical-scavenging activities [32,
33]. More studies on each herbal element of HCEt have been
performed in the search for improved blood circulation. Per-
sicae semen exhibits anticoagulation and thrombotic eﬀects
[34, 35]. Paeonia lactiﬂora inhibits thrombosis and platelet
aggregation, increases ﬁbrinolytic activity, and exhibits an
antioxidant eﬀect [36, 37].
Our results are consistent with previous HCEt studies
in the cerebrovascular system. One decoction of Xue-fu-
xhu-yu (HCEt) increases vertebral basilar artery blood ﬂow
velocityanddecreasespulsalityindexinpatientswithsudden
deafness[38].Leeetal.reportedthatthisdecoctionmarkedly
potentiated the recombinant tissue plasminogen activator
rt-PA-mediated reduction in infarct volume in a cerebral
ischemic region [3]. Our results regarding the eﬀect of HCEt
on CVR supports the result of Lee et al. because the increase
in CVR represents an improvement in cerebrovascular
reserve capacity. Therefore, a decrease in cerebral blood
perfusion can be counterbalanced by a reduction in cortical
vessel resistance to maintain a suﬃcient blood supply in the
brain [19, 39].
One limitation of the present research is the comparison
of current TCD data to historical control data. The potential
bias and compounding factors were minimized as much as
possible despite the limitations of the designed protocols.
The inclusion criteria for subjects and the methods and
devices of TCD examination were identical in the previous
and current studies. The eﬀects of HCEt on both parameters
mayappearsubject-speciﬁc(Figure 3) because TCM exhibits
diﬀerences in individual drug responses. Basically, HCEt was
created for patient with blood stasis syndrome based on the
TCM pattern identiﬁcation theory. Further research of HCEt
should be performed in categorized patients using a blood
stasis syndrome score.
5. Conclusions
We demonstrated that HCEt improved CVR and erythrocyte
deformability. Our results suggest that HCEt increases
blood ﬂow in the cerebral microcirculation by enhancing
erythrocyte deformability. This study provides a basis for
further studies on the eﬀect of HCEt in patients with cere-
bral infarction, especially patients with reduced erythrocyte
deformability and impaired cerebrovascular reactivity.
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